comparemela.com

Latest Breaking News On - Neogenomics company profile - Page 5 : comparemela.com

NeoGenomics (NASDAQ:NEO) Reaches New 1-Year High at $20.75

Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $20.75 and last traded at $20.55, with a volume of 845796 shares traded. The stock had previously closed at $19.24. Analysts Set New Price Targets Several equities research analysts […]

United-states
Piper-sandler
Aliciac-olivo
William-blair
Nasdaq
Highmark-wealth-management
Pharma-services
Neogenomics-inc
Bluepath-capital-management
Morgan-stanley
Goldman-sachs-group
Coppell-advisory-solutions

NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.00 Consensus PT from Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year […]

United-states
Aliciac-olivo
William-blair
Morgan-stanley
Clinical-services
Securities-exchange-commission
Needham-company
Bluepath-capital-management
Highmark-wealth-management
Neogenomics-inc
Tower-research-capital
Neogenomics-company-profile

NeoGenomics (NASDAQ:NEO) Updates FY 2023 Earnings Guidance

NeoGenomics (NASDAQ:NEO – Get Free Report) updated its FY 2023 earnings guidance on Monday. The company provided earnings per share guidance of -$0.18–$0.15 for the period, compared to the consensus earnings per share estimate of -$0.28. The company issued revenue guidance of $585.00 million-$592.00 million, compared to the consensus revenue estimate of $573.19 million. Analyst […]

United-states
William-blair
Piper-sandler
T-rowe-price-investment-management-inc
Goldman-sachs-group
Needham-company
Pharma-services
Neogenomics-inc
Millennium-management
Dimensional-fund-advisors
Norges-bank
Clinical-services

Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $18.42

Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $18.42
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

United-states
William-blair
Piper-sandler
Nasdaq
Citigroup-inc
Metlife-investment-management
Clinical-services
Commonwealth-of-pennsylvania-public-school-empls-retrmt
Goldman-sachs-group
Neogenomics-company-profile
Needham-company
Alphacrest-capital-management

NeoGenomics (NASDAQ:NEO) PT Lowered to $18.00

NeoGenomics (NASDAQ:NEO – Free Report) had its price target lowered by Piper Sandler from $23.00 to $18.00 in a report released on Monday, Benzinga reports. Piper Sandler currently has an overweight rating on the medical research company’s stock. A number of other brokerages also recently issued reports on NEO. Morgan Stanley cut their price objective […]

United-states
William-blair
Piper-sandler
Alphacrest-capital-management
Pharma-services
Metlife-investment-management
Neogenomics-inc
Morgan-stanley
Citigroup-inc
Needham-company
Commonwealth-of-pennsylvania-public-school-empls-retrmt
Clinical-services

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.